Looking to the Future and Where These Agents May Fit in Sequencing

Dr Shadman outlines the key open questions and later-phase data to watch for both programs. For sonrotoclax, already approved as monotherapy in mantle cell lymphoma, frontline chronic lymphocytic leukemia combination data show undetectable measurable residual disease rates exceeding 95%, and two head-to-head CELESTIAL trials, one with completed enrollment using a venetoclax plus obinutuzumab control arm, the other still enrolling, should clarify its frontline role. Sonrotoclax is also being studied with anti-CD20 antibodies in the relapse setting. For the degrader catadegbrutinib, monotherapy data are still maturing toward potential approval, with a head-to-head trial versus pirtobrutinib and ongoing interest in combinations across lines. Dr Shadman expects both agents to move into earlier lines as confidence in their safety and efficacy increases. For practicing hematologist-oncologists, he notes these regimens are currently accessible through clinical trials and encourages discussion, particularly frontline combinations aiming for high rates of undetectable measurable residual disease that many patients may need.